MIR503HG Loss Promotes Endothelial-to-Mesenchymal Transition in Vascular Disease

Affiliations

• ¹ The Queen's Medical Research Institute, Centre for Cardiovascular Science (J.P.M., J.R., A. Caudrillier, J.P.S., A.-M.S., T.D., A.S., L. Deng, S.-H.C., K.S., A.T., T.M., J.I., P.W.F.H., L. Denby, A. Caporali, A.H.B.), University of Edinburgh, Edinburgh, Scotland.
• ² Institute for Cardiovascular Physiology, Goethe University, Frankfurt, Germany (B.P.-M., M.S.L., R.P.B.).
• ³ German Center of Cardiovascular Research (DZHK), Partner site RheinMain, Frankfurt, Germany (B.P.-M., M.S.L., R.P.B.).
• ⁴ Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine (A.v.K.), University of Edinburgh, Edinburgh, Scotland.
• ⁵ The Roslin Institute and Royal (Dick) School of Veterinary Studies (R.S.T.), University of Edinburgh, Edinburgh, Scotland.
• ⁶ The Queen's Medical Research Institute, Centre for Inflammation Research (J.R.W.-K., N.C.H.), University of Edinburgh, Edinburgh, Scotland.
• ⁷ Institute of Cardiovascular and Medical Sciences, British Heart Foundation (BHF) Glasgow Centre, University of Glasgow, Glasgow, United Kingdom (J.D.M., A.C.B.).
• ⁸ BHF Cambridge (CRE), University of Cambridge, Cambridge, United Kingdom (P.C., N.W.M.).
• ⁹ The Zena and Michael A. Wiener Cardiovascular Institute, School of Medicine at Mount Sinai, New York, New York (J.C.K.).
• ¹⁰ Victor Chang Cardiac Research Institute, Darlinghurst, Australia. (J.C.K.).
• ¹¹ Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel (I.U.).